Pharmacy

Healthcare stakeholders can impact a patient’s health by leveraging available capabilities and resources to help achieve better health outcomes and address this opioid epidemic.

Cancer medication spending is unsustainable, but significant savings can be achieved just by reducing waste. Here’s how.

Better care at lower costs is the ultimate goal across healthcare today. Here’s how pharmacists can help.

Specialty pharmaceuticals make up a huge part of the current drug market, and their impact is only going to grow over the next few years.

How can payers cope with new, ultra-expensive therapies?

A new study was conducted to better understand the landscape of coverage of non-pharmacologic treatments for chronic pain among public and private insurers in the United States. Here’s what it found.

UPMC Health Plan has recently entered into two value-based contracts for medications related to treating diabetes and opioid addiction.

What these healthcare industry disruptors are, and how they could impact cost and quality of care.

Innovative PBM performance-based pharmacy networks focus on reducing costs and Improving clinical outcomes

How would you define a specialty pharmaceutical? Chances are, it’s different from the way another healthcare executive would define them.

The hope is that more biosimilars will lead to more access and more affordable medications, but biosimilar uptake is lagging. Here’s why and how FDA hopes to fix it.

Here’s what’s shaking up the drug launch pricing space. Experts weigh in.

FDA issued a recall of popular blood pressure drugs. Here’s what you need to know.

Making medications more affordable to patients is linked to better adherence, with no added costs, according to a new study.

Surprising findings from the largest study to date investigating the genetics of osteoporosis and fracture risk.

Not all therapies work the same in every patient, but that’s not the biggest challenge in treating mental health. This is.

In response to the lack of transparency, health organizations are creating drug pricing tools that deliver patient-specific pricing. Here’s how they work.

A new forecast reveals an important focus point for healthcare execs in the quest to manage pharma costs.

Here are four other things that MCOs should know about a first-of-its kind targeted RNA-based therapy to treat a rare disease.

Basket trials are designed to test therapies that target a specific genetic mutation found in the tumor, regardless of tumor histology. This emerging trend raises a number of key questions for the industry.

Although the act would not prohibit manufacturers from increasing prices, it could change the pricing landscape. Here’s why.

Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.

When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.

Are recent pharma price drops just a response to political pressure or will the momentum last? Managed Healthcare Executive asked industry experts, and here’s what they said.

Amazon captured the industry’s attention once again when it announced it is acquiring online pharmacy PillPack for a reported $1 billion. Here’s how experts say it will affect managed care.

Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.

Prices of more than 20% of generic drugs increased more than 100% between 2010 and 2015.

Recommendations focus on ways to prevent opioid misuse and reduce risk of addiction.

Reference pricing models are emerging as increasingly popular approaches for lowering drug costs.